KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 99 filers reported holding KEROS THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $44,837,021 | -5.7% | 1,406,431 | +18.8% | 0.00% | 0.0% |
| Q2 2023 | $47,564,239 | +6.3% | 1,183,779 | +12.9% | 0.00% | 0.0% |
| Q1 2023 | $44,752,247 | -10.8% | 1,048,062 | +0.3% | 0.00% | 0.0% |
| Q4 2022 | $50,196,267 | +47.2% | 1,045,320 | +15.3% | 0.00% | 0.0% |
| Q3 2022 | $34,105,000 | +60.0% | 906,574 | +17.5% | 0.00% | 0.0% |
| Q2 2022 | $21,320,000 | -46.8% | 771,618 | +4.8% | 0.00% | 0.0% |
| Q1 2022 | $40,056,000 | -6.7% | 736,593 | +0.4% | 0.00% | 0.0% |
| Q4 2021 | $42,930,000 | +52.9% | 733,720 | +3.4% | 0.00% | 0.0% |
| Q3 2021 | $28,078,000 | -1.1% | 709,761 | +6.2% | 0.00% | 0.0% |
| Q2 2021 | $28,378,000 | -23.5% | 668,203 | +10.9% | 0.00% | 0.0% |
| Q1 2021 | $37,092,000 | -11.2% | 602,646 | +1.8% | 0.00% | 0.0% |
| Q4 2020 | $41,778,000 | +262.4% | 592,255 | +98.1% | 0.00% | – |
| Q3 2020 | $11,529,000 | -1.6% | 298,931 | -4.3% | 0.00% | – |
| Q2 2020 | $11,719,000 | – | 312,407 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,412,705 | $99,652,000 | 10.82% |
| CHI Advisors LLC | 433,852 | $30,604,000 | 8.62% |
| VR Adviser, LLC | 672,306 | $47,424,000 | 6.97% |
| Consonance Capital Management LP | 557,095 | $39,297,000 | 3.67% |
| Logos Global Management LP | 450,000 | $31,743,000 | 2.72% |
| RA Capital Management | 1,875,000 | $132,263,000 | 1.85% |
| Nantahala Capital Management | 534,514 | $37,705,000 | 1.17% |
| Orbimed Advisors | 1,679,417 | $118,466,000 | 1.04% |
| Eventide Asset Management | 346,000 | $24,407,000 | 0.37% |
| Atom Investors LP | 49,981 | $3,526,000 | 0.36% |